Therapeutic strategies to overcome taxane resistance in cancer
One of the primary causes of attenuated or loss of efficacy of cancer chemotherapy is the
emergence of multidrug resistance (MDR). Numerous studies have been published …
emergence of multidrug resistance (MDR). Numerous studies have been published …
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition
KM Hanssen, M Haber, JI Fletcher - Drug Resistance Updates, 2021 - Elsevier
Resistance to chemotherapy remains one of the most significant obstacles to successful
cancer treatment. While inhibiting drug efflux mediated by ATP-binding cassette (ABC) …
cancer treatment. While inhibiting drug efflux mediated by ATP-binding cassette (ABC) …
Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells
Overexpression of ATP-binding cassette (ABC) transporters is one of the most important
mechanisms responsible for the development of multidrug resistance (MDR). Selonsertib, a …
mechanisms responsible for the development of multidrug resistance (MDR). Selonsertib, a …
Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2
CP Wu, SH Hsiao, YS Wu - Drug Resistance Updates, 2023 - Elsevier
The overexpression of the human ATP-binding cassette (ABC) transporters in cancer cells is
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …
The role of ABCC10/MRP7 in anti-cancer drug resistance and beyond
Abstract Multidrug resistance protein 7 (MRP7), also known as ATP-binding cassette (ABC)
transporter subfamily C10 (ABCC10), is an ABC transporter that was first identified in 2001 …
transporter subfamily C10 (ABCC10), is an ABC transporter that was first identified in 2001 …
H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo
Y Yang, D Guan, L Lei, J Lu, JQ Liu, G Yang… - Toxicology and applied …, 2018 - Elsevier
Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment, in which
the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α …
the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α …
[HTML][HTML] Repurposing tyrosine kinase inhibitors to overcome multidrug resistance in cancer: a focus on transporters and lysosomal sequestration
M Krchniakova, J Skoda, J Neradil, P Chlapek… - International journal of …, 2020 - mdpi.com
Tyrosine kinase inhibitors (TKIs) are being increasingly used to treat various malignancies.
Although they were designed to target aberrant tyrosine kinases, they are also intimately …
Although they were designed to target aberrant tyrosine kinases, they are also intimately …
[HTML][HTML] VS-4718 antagonizes multidrug resistance in ABCB1-and ABCG2-overexpressing cancer cells by inhibiting the efflux function of ABC transporters
Overexpression of ATP-binding cassette (ABC) transporters is one of the most important
mechanisms responsible for multi-drug resistance (MDR). VS-4718, a tyrosine kinase …
mechanisms responsible for multi-drug resistance (MDR). VS-4718, a tyrosine kinase …
Dual inhibitors as a new challenge for cancer multidrug resistance treatment
T Stanković, J Dinić, A Podolski-Renić… - Current Medicinal …, 2019 - ingentaconnect.com
Background: Dual-targeting in cancer treatment by a single drug is an unconventional
approach in relation to drug combinations. The rationale for the development of …
approach in relation to drug combinations. The rationale for the development of …
Ulixertinib (BVD-523) antagonizes ABCB1-and ABCG2-mediated chemotherapeutic drug resistance
Abstract Ulixertinib (BVD-523) is a highly potent, selective, and reversible ERK1/2 inhibitor
and is currently in clinical development for the treatment of advanced solid tumors. In this …
and is currently in clinical development for the treatment of advanced solid tumors. In this …